With increasing information overload and packed work schedules, staying up-to-date on the newest oncologic advances is harder than ever. But take heart! The QuadShot is freshly brewed in your inbox four mornings each week so you can quickly down and digest the day's most pertinent cancer news.
While no one is quite as good at it as the VA, rates of active surveillance and watchful waiting for low-risk prostate cancer are higher than ever according to the latest SEER analysis. In fact, it's now the most popular treatment of all. | Mahal, JAMA 2019